Vitamin D metabolites and bioactive parathyroid hormone levels during Spacelab 2. 1988

E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
Space Biology Branch, NASA-Ames Research Center, Moffett Field, CA 94035.

The purpose of this study was to determine whether plasma levels of the vitamin D hormone and parathyroid hormone (PTH), two potent activators of bone remodeling sites, were altered in four astronauts during the 8-day (d) Spacelab 2 mission (SL2). Increased circulating levels of either hormone could change calcium homeostasis and bone cell activity and, thus, contribute to bone loss in crewmembers in space. The vitamin D hormone was elevated in all astronauts at the end of the first inflight day but returned to normal by the seventh day. Biologically active PTH tended to be normal throughout the mission. Both hormones were within the normal range by the end of the 8-d flight of this SL2 crew. Plasma levels of 25OHD, 24,25(OH)2D, calcium, phosphorus, and albumin were essentially normal during the mission.

UI MeSH Term Description Entries
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002112 Calcifediol The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. 25-Hydroxycholecalciferol,25-Hydroxyvitamin D 3,25-Hydroxycholecalciferol Monohydrate,25-Hydroxyvitamin D3,Calcidiol,Calcifediol Anhydrous,Calcifediol, (3 alpha,5Z,7E)-Isomer,Calcifediol, (3 beta,5E,7E)-Isomer,Calderol,Dedrogyl,Hidroferol,25 Hydroxycholecalciferol,25 Hydroxycholecalciferol Monohydrate,25 Hydroxyvitamin D 3,25 Hydroxyvitamin D3,Anhydrous, Calcifediol,Monohydrate, 25-Hydroxycholecalciferol
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D004100 Dihydroxycholecalciferols Cholecalciferols substituted with two hydroxy groups in any position. Dihydroxyvitamins D
D006706 Homeostasis The processes whereby the internal environment of an organism tends to remain balanced and stable. Autoregulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013026 Space Flight Travel beyond the earth's atmosphere. Space Exploration,Space Travel,Spaceflight,Exploration, Space,Explorations, Space,Flight, Space,Flights, Space,Space Explorations,Space Flights,Space Travels,Spaceflights,Travel, Space,Travels, Space
D014807 Vitamin D A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
D015650 24,25-Dihydroxyvitamin D 3 A physiologically active metabolite of VITAMIN D. The compound is involved in the regulation of calcium metabolism, alkaline phosphatase activity, and enhancing the calcemic effect of CALCITRIOL. 24,25-Dihydroxycholecalciferol,(24R)-24,25-Dihydroxyvitamin D3,24,25 Dihydroxyvitamin D3,24,25-Dihydroxyvitamin D 3, (3beta,5Z,7E,24R)-Isomer,24,25-Dihydroxyvitamin D3,24R,25-Dihydroxycholecalciferol,24,25 Dihydroxycholecalciferol,24,25 Dihydroxyvitamin D 3,24R,25 Dihydroxycholecalciferol,Dihydroxyvitamin D3, 24,25

Related Publications

E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
January 2023, American journal of kidney diseases : the official journal of the National Kidney Foundation,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
May 2022, Children (Basel, Switzerland),
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
November 1980, The American journal of physiology,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
January 1995, Mineral and electrolyte metabolism,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
January 1990, Clinical therapeutics,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
December 2009, Atherosclerosis,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
December 1986, Bone and mineral,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
April 1986, European journal of pediatrics,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
April 1966, The Yale journal of biology and medicine,
E R Morey-Holton, and H K Schnoes, and H F DeLuca, and M E Phelps, and R F Klein, and R H Nissenson, and C D Arnaud
April 1963, Journal of chronic diseases,
Copied contents to your clipboard!